316 related articles for article (PubMed ID: 2671283)
1. Adjuvant CMFVP versus melphalan for operable breast cancer with positive axillary nodes: 10-year results of a Southwest Oncology Group Study.
Rivkin SE; Green S; Metch B; Glucksberg H; Gad-el-Mawla N; Constanzi JJ; Hoogstraten B; Athens J; Maloney T; Osborne CK
J Clin Oncol; 1989 Sep; 7(9):1229-38. PubMed ID: 2671283
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study.
Rivkin SE; Green SJ; Lew D; Costanzi JJ; Athens JW; Osborne CK; Vaughn CB; Martino S
Cancer; 2003 Jan; 97(1):21-9. PubMed ID: 12491501
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant CMFVP versus adjuvant CMFVP plus ovariectomy for premenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study.
Rivkin SE; Green S; O'Sullivan J; Cruz AB; Abeloff MD; Jewell WR; Costanzi JJ; Farrar WB; Osborne CK
J Clin Oncol; 1996 Jan; 14(1):46-51. PubMed ID: 8558219
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study.
Rivkin SE; Green S; Metch B; Cruz AB; Abeloff MD; Jewell WR; Costanzi JJ; Farrar WB; Minton JP; Osborne CK
J Clin Oncol; 1994 Oct; 12(10):2078-85. PubMed ID: 7931477
[TBL] [Abstract][Full Text] [Related]
5. Combination chemotherapy (CMFVP) versus L-phenylalanine mustard (L-PAM) for operable breast cancer with positive axillary nodes: a Southwest Oncology Group Study.
Glucksberg H; Rivkin SE; Rasmussen S; Tranum B; Gad-el-Mawla N; Costanzi J; Hoogstraten B; Athens J; Maloney T; McCracken J; Vaughn C
Cancer; 1982 Aug; 50(3):423-34. PubMed ID: 7046900
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant therapy of breast cancer: Southwest Oncology Group studies.
Osborne CK; Rivkin SE; McDivitt RW; Green S; Stephens RL; Costanzi JJ; O'Bryan R
NCI Monogr; 1986; (1):71-4. PubMed ID: 3534592
[TBL] [Abstract][Full Text] [Related]
7. One versus 2 years of CMFVP adjuvant chemotherapy in axillary node-positive and estrogen receptor-negative patients: a Southwest Oncology Group study.
Rivkin SE; Green S; Metch B; Jewell WR; Costanzi JJ; Altman SJ; Minton JP; O'Bryan RM; Osborne CK
J Clin Oncol; 1993 Sep; 11(9):1710-6. PubMed ID: 8355037
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant therapy of breast cancer: the Southwest Oncology Group experience.
Knight WA; Rivkin SE; Glucksberg H; Foulkes MA; Costanzi JJ; Stephens RL; Athens JW; O'Bryan RM
Breast Cancer Res Treat; 1983; 3 Suppl():S27-33. PubMed ID: 6367857
[TBL] [Abstract][Full Text] [Related]
9. Short-course FAC-M versus 1 year of CMFVP in node-positive, hormone receptor-negative breast cancer: an intergroup study.
Budd GT; Green S; O'Bryan RM; Martino S; Abeloff MD; Rinehart JJ; Hahn R; Harris J; Tormey D; O'Sullivan J
J Clin Oncol; 1995 Apr; 13(4):831-9. PubMed ID: 7707108
[TBL] [Abstract][Full Text] [Related]
10. Postsurgical adjuvant chemotherapy of stage II breast carcinoma with or without crossover to a non-cross-resistant regimen: a Cancer and Leukemia Group B study.
Perloff M; Norton L; Korzun AH; Wood WC; Carey RW; Gottlieb A; Aust JC; Bank A; Silver RT; Saleh F; Canellos GP; Perry MC; Weiss RB; Holland JF
J Clin Oncol; 1996 May; 14(5):1589-98. PubMed ID: 8622076
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant chemotherapy for operable breast cancer with positive axillary nodes: a comparison of CMFVP versus L-PAM.
Rivkin SE; Glucksberg H; Foulkes M; Osborne CK; Tranum W; Gad-el-Mawla N; Constanzi J
World J Surg; 1985 Oct; 9(5):719-22. PubMed ID: 3840628
[No Abstract] [Full Text] [Related]
12. A randomized trial of five and three drug chemotherapy and chemoimmunotherapy in women with operable node positive breast cancer.
Tormey DC; Weinberg VE; Holland JF; Weiss RB; Glidewell OJ; Perloff M; Falkson G; Falkson HC; Henry PH; Leone LA
J Clin Oncol; 1983 Feb; 1(2):138-45. PubMed ID: 6366133
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. An intergroup study.
Mansour EG; Gray R; Shatila AH; Osborne CK; Tormey DC; Gilchrist KW; Cooper MR; Falkson G
N Engl J Med; 1989 Feb; 320(8):485-90. PubMed ID: 2915651
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy versus observation in high-risk node-negative breast cancer patients.
Mansour EG; Eudey L; Tormey DC; Shatila AH; Osborne CK; Gilchrist KW; Cooper MR; Falkson G
J Natl Cancer Inst Monogr; 1992; (11):97-104. PubMed ID: 1627437
[TBL] [Abstract][Full Text] [Related]
15. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial.
Leonard RC; Lind M; Twelves C; Coleman R; van Belle S; Wilson C; Ledermann J; Kennedy I; Barrett-Lee P; Perren T; Verrill M; Cameron D; Foster E; Yellowlees A; Crown J;
J Natl Cancer Inst; 2004 Jul; 96(14):1076-83. PubMed ID: 15265969
[TBL] [Abstract][Full Text] [Related]
16. Comparison of different trials of adjuvant chemotherapy in stage II breast cancer using a natural history data base.
Jones SE; Moon TE; Bonadonna G; Valagussa P; Rivkin S; Buzdar A; Montague E; Powles T
Am J Clin Oncol; 1987 Oct; 10(5):387-95. PubMed ID: 3310603
[TBL] [Abstract][Full Text] [Related]
17. Comparison of adjuvant chemotherapy with methotrexate and fluorouracil with and without cyclophosphamide in breast cancer patients with one to three positive axillary lymph nodes.
Shapiro CL; Gelman RS; Hayes DF; Osteen R; Obando A; Canellos GP; Frei E; Henderson IC
J Natl Cancer Inst; 1993 May; 85(10):812-7. PubMed ID: 8487326
[TBL] [Abstract][Full Text] [Related]
18. Proportional hazards and recursive partitioning and amalgamation analyses of the Southwest Oncology Group node-positive adjuvant CMFVP breast cancer data base: a pilot study.
Albain KS; Green S; LeBlanc M; Rivkin S; O'Sullivan J; Osborne CK
Breast Cancer Res Treat; 1992; 22(3):273-84. PubMed ID: 1391993
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration.
Misset JL; di Palma M; Delgado M; Plagne R; Chollet P; Fumoleau P; Le Mevel B; Belpomme D; Guerrin J; Fargeot P; Metz R; Ithzaki M; Hill C; Mathé G
J Clin Oncol; 1996 Apr; 14(4):1136-45. PubMed ID: 8648368
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant chemotherapy in operable breast cancer: cyclophosphamide, methotrexate, and fluorouracil versus chlorambucil, methotrexate, and fluorouracil--11-year results of Swiss Group for Clinical Cancer Research trial SAKK 27/82.
Senn HJ; Maibach R; Castiglione M; Jungi WF; Cavalli F; Leyvraz S; Obrecht JP; Schildknecht O; Siegenthaler P
J Clin Oncol; 1997 Jul; 15(7):2502-9. PubMed ID: 9215818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
